SCHEMBL3087622

SCHEMBL3087622

CCN(CCc1ccc(Cl)c(CO[Si](C)(C)C(C)(C)C)c1)C(=O)OC(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 1/20 0.35
NAMPT P43490 1/20 0.34
FFAR1 O14842 2/20 0.34
FFAR4 Q5NUL3 2/20 0.34
POLB P06746 1/20 0.33
HDAC3 O15379 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33
NCOR2 Q9Y618 2/20 0.33
BACE1 P56817 1/20 0.33
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
LMNA P02545 1/20 0.32
TSHR P16473 1/20 0.32
SIGMAR1 Q99720 2/20 0.31
AHCY P23526 1/20 0.31
ALDH1A1 P00352 2/20 0.31
TP53 P04637 2/20 0.31
MAPT P10636 2/20 0.31
GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3079714 0.90 HDAC3 (0.38) NAMPTPOLBHDAC3HDAC1HDAC2
SCHEMBL1751384 0.88 ADRB3 (0.38) ADRB3FFAR1FFAR4BACE1MEN1
SCHEMBL3084243 0.88 CDK8 (0.38) FFAR1FFAR4BACE1MEN1KMT2A
SCHEMBL3080688 0.84 TSHR (0.36) NAMPTFFAR1FFAR4POLBHDAC3
SCHEMBL1750783 0.83 REN (0.35)
SCHEMBL1751218 0.83 SSTR4 (0.35) ADRB3NAMPTHDAC3HDAC1HDAC2
SCHEMBL3075616 0.81 HTR2C (0.39) BACE1MEN1KMT2A
SCHEMBL1750843 0.80 LPAR1 (0.35) ADRB3HDAC3HDAC1HDAC2NCOR2
SCHEMBL3095965 0.79 LPAR1 (0.34) HDAC3HDAC1HDAC2NCOR2BACE1
SCHEMBL1752399 0.77 REN (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324052-A1 NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES BEZENCON OLIVIER 2010-12-23 US disclosed
US-7799805-B2 Piperidine carboxylic acid amide derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-21 US disclosed
US-20080214598-A1 Novel Piperidine Carboxylic Acid Amide Derivatives ACTELION PHARMACEUTICALS LTD (CH) 2008-09-04 US disclosed
EP-1893578-A2 NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2008-03-05 EP disclosed
WO-2006129237-A2 NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214598-A1 Novel Piperidine Carboxylic Acid Amide Derivatives REN, ACE, AGTR2 ADRB3 364/4885NAMPT 518/4885FFAR1 1178/4885
US-20100324052-A1 NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES REN, ACE, AGTR2 ADRB3 157/4885NAMPT 615/4885FFAR1 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.